Vivani Medical Announces Public Filing of Registration Statement for the Proposed Initial Public Offering of Cortigent, Inc., a Subsidiary Advancing the Business of its Neuromodulation Division Business Wire - Tue Mar 21, 5:00AM CDT
Business Wire
Tue Mar 21, 5:00AM CDT
Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, today announced the filing of a Registration Statement on Form S-1 with...
Vivani Medical Reports Third Quarter 2022 Results and Provides Business Updates Business Wire - Mon Nov 14, 2022
Business Wire
Mon Nov 14, 2022
Vivani Medical, Inc. (Nasdaq: VANI) (“Vivani” or the “Company”), a biopharmaceutical company developing miniaturized, long-term drug implants including lead asset NPM-119 for the treatment of patients with type 2 diabetes, today announced...
Vivani Medical to Present at the ThinkEquity Investor Conference Business Wire - Mon Oct 17, 2022
Business Wire
Mon Oct 17, 2022
Vivani Medical, Inc. (NASDAQ: VANI) (the “Company” or “Vivani”), an innovative, clinical-stage biopharmaceutical company that develops novel, long-term therapeutic implants, announced today that it will present at the upcoming ThinkEquity investor...